Treatment outcomes following continuous miglustat therapy in
Por um escritor misterioso
Last updated 29 setembro 2024
Background Niemann-Pick disease Type C (NP-C) is a rare, progressive neurodegenerative disorder characterized by progressive neurodegeneration and premature death. We report data at closure of the NPC Registry that describes the natural history, disease course and treatment experience of NP-C patients in a real-world setting. Methods The NPC Registry was a prospective observational cohort study that ran between September 2009 and October 2017. Patients with a confirmed diagnosis of NP-C were enrolled regardless of treatment status. All patients underwent clinical assessments and medical care as determined by their physicians; data were collected through a secure internet-based portal. Results At closure on October 19, 2017, 472 patients from 22 countries were enrolled in the NPC Registry. Mean (standard deviation) age at enrollment was 21.2 (15.0) years, and 51.9% of patients were male. First neurological symptom onset occurred during the early-infantile (< 2 years), late-infantile (2 to < 6 years), juvenile (6 to < 15 years), or adolescent/adult (≥ 15 years) periods in 13.5, 25.6, 31.8, and 29.1% of cases, respectively. The most frequent neurological manifestations prior to enrollment included ataxia (67.9%), vertical supranuclear gaze palsy (67.4%), dysarthria (64.7%), cognitive impairment (62.7%), dysphagia (49.1%), and dystonia (40.2%). During infancy, splenomegaly and hepatomegaly were frequent (n = 199/398 [50%] and n = 147/397 [37.0%], respectively) and persisted in most affected patients. Of the 472 enrolled patients, 241 were continuously treated with miglustat during the NPC Registry observation period, of whom 172 of these 241 patients were treated continuously for ≥12 months. A composite disability score that assesses impairment of ambulation, manipulation, language, and swallowing was highest in the early-infantile population and lowest in the adolescent/adult population. Among the continuous miglustat therapy population, 70.5% of patients had improved or had stable disease (at least 3 of the 4 domains having a decreased or unchanged score between enrollment and last follow-up). The NPC Registry did not identify any new safety signals associated with miglustat therapy. Conclusions The profiles of clinical manifestations in the final NPC Registry dataset agreed with previous clinical descriptions. Miglustat therapy was associated with a stabilization of neurological manifestations in most patients. The safety and tolerability of miglustat therapy was consistent with previous reports.
Proportions of patients who received continuous miglustat therapy
Clinical trials with Miglustat (Zavesca ® )
Small Molecules: Substrate Inhibitors, Chaperones, Stop-Codon Read
Estimating the prevalence of Niemann-Pick disease type C (NPC) in
PDF) Treatment outcomes following continuous miglustat therapy in
PDF) Treatment outcomes following continuous miglustat therapy in
COVID-19 therapeutics: Challenges and directions for the future
These highlights do not include all the information needed to use
The development and use of small molecule inhibitors of
JCM, Free Full-Text
Stable or improved neurological manifestations during miglustat
Estimating the prevalence of Niemann-Pick disease type C (NPC) in
Treatment outcomes following continuous miglustat therapy in
Effects of Miglustat on Stabilization of Neurological Disorder in
Miglustat: Package Insert
Recomendado para você
-
Parents of kids with Niemann Pick C advocate for adrabetadex29 setembro 2024
-
Potential treatment for Niemann-Pick type C, a rare neurodegenerative disease29 setembro 2024
-
Anesthetic consideration of Niemann-Pick Disease type C29 setembro 2024
-
Parents of twins with Niemann-Pick find a treatment29 setembro 2024
-
Psychiatric and Cognitive Symptoms Associated with Niemann-Pick Type C Disease: Neurobiology and Management29 setembro 2024
-
Niemann Pick Disease - Rivin29 setembro 2024
-
Niemann–Pick disease29 setembro 2024
-
Diagnostic and predictive methods for a Niemann-Pick disease type29 setembro 2024
-
Rare Diseases India on X: Niemann-Pick is a rare, inherited29 setembro 2024
-
Hepatocellular carcinoma as a complication of Niemann‐Pick disease29 setembro 2024
você pode gostar
-
E3 2016: Here's What's in Forza Horizon 3's $100 Ultimate Edition - GameSpot29 setembro 2024
-
4 square Full episodes - balance, everybody knows I love my toes29 setembro 2024
-
Pokemon Center Kyoto - 2020 All You Need to Know BEFORE You Go (with Photos) - Tripadvisor29 setembro 2024
-
Now Is Not the Time to Panic by Kevin Wilson29 setembro 2024
-
The extreme logistics behind Formula One's global circus - FreightWaves29 setembro 2024
-
CosmoLiving by Cosmopolitan Gold Acrylic Tic Tac Toe Game Set with29 setembro 2024
-
Jogo Minecraft Xbox 360 edition29 setembro 2024
-
Emma (Yakusoku no Neverland) - Zerochan Anime Image Board29 setembro 2024
-
Baixar cidade: jogo de carro para PC - LDPlayer29 setembro 2024
-
How about the Game of LIFE?29 setembro 2024